Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference
April 23 2018 - 7:05AM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, announced that Chief Executive Officer
Frederic Ors will present an update on the Company's recent
progress and future strategy at the Bloom Burton & Co.
Healthcare Investor Conference 2018 in Toronto, Canada.
Details of the presentation are as follows:
- Date: Thursday, May 3, 2018
- Time: 2:30 pm ET
- Location: Hall B, Lower Concourse Level of the Sheraton Centre
Toronto Hotel, Toronto, Canada
About the Conference Bloom Burton & Co.
Healthcare Investor Conference brings together U.S., Canadian and
international investors who are interested in the latest
development in the Canadian healthcare sector. Attendees will have
an opportunity to obtain corporate updates from premier Canadian
publicly traded and private companies through presentations and
private meetings.
About ImmunovaccineImmunovaccine Inc. is a
clinical-stage biopharmaceutical company dedicated to making
immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and infectious diseases.
Immunovaccine develops T cell activating cancer immunotherapies
based on the Company’s proprietary drug delivery platform. This
patented technology provides controlled and prolonged exposure to a
broad range of immunogenic stimuli. Immunovaccine has advanced two
T cell-activating therapies for cancer through Phase 1 human
clinical trials and is currently conducting a Phase 1b study with
Incyte Corporation assessing its lead cancer therapy, DPX-Survivac,
as a combination therapy in ovarian cancer. The Company is also
exploring additional applications of its platform, including
DPX-RSV, an innovative vaccine candidate for respiratory syncytial
virus (RSV), which has recently completed a Phase 1 clinical trial.
Immunovaccine also has ongoing clinical projects in malaria and
Zika virus. Connect at www.imvaccine.com.
Contacts for Immunovaccine:
MEDIA Mike Beyer, Sam Brown
Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSPierre Labbé, Chief
Financial OfficerT: (902) 492-1819
E: info@imvaccine.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024